Literature DB >> 14656481

MIS/AMH in the assessment of cryptorchidism and intersex conditions.

Mary M Lee1, Madhusmita Misra, Patricia K Donahoe, David T MacLaughlin.   

Abstract

Mullerian inhibiting substance (MIS), also known as anti-Mullerian hormone (AMH), causes Mullerian duct involution during male sexual differentiation and also has a postnatal regulatory role in the gonads. Serum MIS/AMH has a gonad specific pattern of expression and its concentrations are sexually dimorphic in children; hence measurement of serum MIS/AMH helps in the evaluation of children with gonadal disorders. In boys with cryptorchidism (non-palpable gonads), serum MIS/AMH correlates with testicular tissue. A measurable value is predictive of undescended testes while an undetectable value is highly suggestive of anorchia. In minimally virilized phenotypic females, MIS/AMH helps differentiate between gonadal and non-gonadal causes of virilization. In children with intersex conditions, MIS/AMH values assist differential diagnosis: a value above the normal female range is predictive of testicular tissue, while an undetectable value is suggestive of absent testicular tissue. Thus, MIS/AMH is useful for delineating gonadal pathology and facilitates the differential diagnosis and management of children with diverse gonadal disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656481     DOI: 10.1016/j.mce.2003.09.014

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  20 in total

Review 1.  Mini puberty and its interpretation.

Authors:  Selim Kurtoğlu; Osman Baştuğ
Journal:  Turk Pediatri Ars       Date:  2014-09-01

2.  Persistent Mullerian duct syndrome: a rare cause of unilateral cryptorchidism.

Authors:  Laura Keukens; Gerda Zijp; Dick Mul
Journal:  BMJ Case Rep       Date:  2012-09-12

Review 3.  Diagnosis of diseases of steroid hormone production, metabolism and action.

Authors:  John W Honour
Journal:  J Clin Res Pediatr Endocrinol       Date:  2009-08-02

4.  Serum AMH concentration as a marker evaluating gonadal function in boys operated on for unilateral cryptorchidism between 1st and 4th year of life.

Authors:  Ewa Matuszczak; Adam Hermanowicz; Wojciech Debek; Marzanna Oksiuta; Ewa Dzienis-Koronkiewicz; Beata Zelazowska-Rutkowska
Journal:  Endocrine       Date:  2011-10-29       Impact factor: 3.633

5.  Serum AMH concentration as a marker evaluating gonadal function in boys operated on for unilateral cryptorchidism between 1st and 4th year of life-why patients with inguinal hernia served as controls.

Authors:  Ewa Matuszczak; Adam Hermanowicz; Wojciech Debek
Journal:  Endocrine       Date:  2012-06       Impact factor: 3.633

Review 6.  Anti-müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologist.

Authors:  Nathalie Josso; Rodolfo A Rey; Jean-Yves Picard
Journal:  Int J Endocrinol       Date:  2013-12-08       Impact factor: 3.257

7.  Anti-Müllerian hormone as an indicator of hemi-castrated unilateral cryptorchid horses.

Authors:  Harutaka Murase; Shigeaki Saito; Tomohiko Amaya; Fumio Sato; Barry Allen Ball; Yasuo Nambo
Journal:  J Equine Sci       Date:  2015-03-31

Review 8.  Anti-müllerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development.

Authors:  Marie Lindhardt Johansen; Casper P Hagen; Trine Holm Johannsen; Katharina M Main; Jean-Yves Picard; Anne Jørgensen; Ewa Rajpert-De Meyts; Anders Juul
Journal:  Int J Endocrinol       Date:  2013-12-03       Impact factor: 3.257

Review 9.  Serum AMH in Physiology and Pathology of Male Gonads.

Authors:  Ewa Matuszczak; Adam Hermanowicz; Marta Komarowska; Wojciech Debek
Journal:  Int J Endocrinol       Date:  2013-10-24       Impact factor: 3.257

Review 10.  Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers.

Authors:  Zehra Jamil; Syeda Sadia Fatima; Khalid Ahmed; Rabia Malik
Journal:  Dis Markers       Date:  2016-02-10       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.